Stempeutics Research Pvt. Ltd has recently launched a stem cell company, Stem Cell research & therapeutics facility at the Manipal University campus, to facilitate the stem cell research in Bangalore and the other areas. The state of the art facility will be located at the Shirdi Sai Baba Cancer Hospital. It will be helpful for the patients with diseases like Dilated Cardio Myopathy, End Stage Lever Disease and Osteoarthritis.

Stempeutics manufacturing facility at Manipal is cGMP (current Good Manufacturing Practice) compliant. The facility is close to 5000 sq ft big with the state-of-art laboratory equipments and two class 10K clean rooms. It has been designed to meet the future plan of accreditation requirements of the USA Foundation for the Accreditation of cellular therapy (FACT) and the manufacturing process will adhere to cGTP (current Good Tissue Practice).

Speaking at Press conference Dr Satish Totey, Chief Scientific Officer, Stempeutics Research said,

“Our mission is to ethically and scientifically explore the full potential of stem cells to transform medicine and offer new hope to millions of people. There will be continuous research for each disease so as to improve product development for effective therapy. Research will be conducted on effective cell number, route of transplantation etc. Further research will be carried out to develop lineage specific cells or precursor cells for more effective therapy. He said that Stempeutics will use the animal house at the University for doing Pre Clinical studies.”

Stempeutics goal is to develop allogenic stem cell therapy in the near future so as to make this therapy more affordable, readily available off the shelf and also to be used in critical conditions. Stempeutics is the first company to employ a global hybrid model where it offers both autologus and allogenic stem cell therapy for various diseases.

Source:moneycontrolindia.com